Floatz logo

Oprelvekin

Waldenström Macroglobulinemia

National Cancer Institute (NCI)protein_peptidePhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

60 Active assets in the Waldenström Macroglobulinemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2BBB
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BBB
Fludarabine
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
Inno-206
BeOne Medicines
Phase 2BBB
PREDNISONE TABLETS
BeOne Medicines
Phase 2BBB

View all 50 →

Same molecule, other indications

Oprelvekin is also rated in:

von Willebrand disease (hereditary or acquired)Dormant
CCC
Indicative ·
55 / 100
View asset →
hemophilia ADormant
CCC
Indicative ·
52 / 100
View asset →
follicular lymphomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →